We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

A Phase III Study of NK105 in Patients With Breast Cancer

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 19, 2012
Last Update Posted: February 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Nippon Kayaku Co.,Ltd.
To verify the non-inferiority of NK105, a paclitaxel-incorporating micellar nanoparticle, to paclitaxel in terms of the progression-free survival in patients with metastatic or recurrent breast cancer.

Condition Intervention Phase
Breast Cancer Nos Metastatic Recurrent Drug: NK105 Drug: Paclitaxel Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer

Resource links provided by NLM:

Further study details as provided by Nippon Kayaku Co.,Ltd.:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: 4.2 years ]

Enrollment: 436
Study Start Date: July 2012
Study Completion Date: January 2017
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NK105 Drug: NK105
IV, Weekly
Active Comparator: Paclitaxel Drug: Paclitaxel
IV, Weekly

Detailed Description:
This study is a randomized, open-label, multi-national phase III study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent of the patient signed by herself.
  • Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.
  • Aged 20 to 74 at the time of informed consent.

Exclusion Criteria:

  • Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01644890

Japan Sites
Tokyo, etc., Japan
Sponsors and Collaborators
Nippon Kayaku Co.,Ltd.
Study Director: Call +81-3-6731-5200 Mon - Fri 9 AM - 5 PM (Japan Time) Nippon Kayaku Co.,Ltd.
  More Information

Responsible Party: Nippon Kayaku Co.,Ltd.
ClinicalTrials.gov Identifier: NCT01644890     History of Changes
Other Study ID Numbers: A3105301
First Submitted: July 17, 2012
First Posted: July 19, 2012
Last Update Posted: February 3, 2017
Last Verified: February 2016

Keywords provided by Nippon Kayaku Co.,Ltd.:
NK105, Paclitaxel, Breast cancer, Micelle

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action